Osteonekrose af kæberne er blevet rapporteret overvejende hos patienter med cancer, som får et behandlingsregime, der også omfatter bisfosfonater, herunder zoledronsyre.
Osteonecrosis of the jaw has been reported predominantly in patients with cancer receiving treatment regimens including bisphosphonates, including zoledronic acid.